Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells

International Immunopharmacology

Volumn 7, Issue 11, 2007, Pages 1422-1432

  Matsuoka, Hideaki ^a   Fujimura, Takao ^a   Mori, Hiroaki ^a   Aramori, Ichiro ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

FR235222; Histone deacetylase; IL 2; Immunosuppression; Inhibitor; NF B

Indexed keywords

CYCLOSPORIN A; FR 235222; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; LUCIFERASE; TACROLIMUS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; COMPREHENSION; CONCENTRATION (PARAMETERS); DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ASSAY; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INTROSPECTION; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HISTONE DEACETYLASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; JURKAT CELLS; NF-KAPPA B; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN SUBUNITS; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

EID: 34548134832     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.05.022     Document Type: Article

References (43)

1. Smith K.A. Interleukin-2. Curr Opin Immunol 4 3 (1992) 271-276
2. Takahashi I., Miyaji H., Yoshida T., Sato S., and Mizukami T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot (Tokyo) 49 5 (1996) 453-457
3. Mori H., Urano Y., Abe F., Furukawa S., Furukawa S., Tsurumi Y., et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 56 2 (2003) 72-79
4. Mori H., Abe F., Furukawa S., Furukawa S., Sakai F., Hino M., et al. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. J Antibiot (Tokyo) 56 2 (2003) 80-86
5. Grozinger C.M., and Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9 1 (2002) 3-16
6. Khochbin S., Verdel A., Lemercier C., and Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11 2 (2001) 162-166
7. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 4 (2002) 287-299
8. Remiszewski S.W. Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr Opin Drug Discov Devel 5 4 (2002) 487-499
9. Rao A., Luo C., and Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15 (1997) 707-747
10. Shapiro R., Jordan M., Scantlebury V.P., Vivas C., Gritsch H.A., Rao A.S., et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. Clin Transpl (1994) 229-236
11. Mohamed M.A., Robertson H., Booth T.A., Balupuri S., Kirby J.A., and Talbot D. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 69 5 (2000) 1002-1005
12. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., and Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5 11 (1999) 1298-1302
13. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 47 3 (1994) 315-323
14. Grabstein K., Dower S., Gillis S., Urdal D., and Larsen A. Expression of interleukin 2, interferon-gamma, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol 136 12 (1986) 4503-4508
15. Testi R., Phillips J.H., and Lanier L.L. Constitutive expression of a phosphorylated activation antigen (Leu 23) by CD3bright human thymocytes. J Immunol 141 8 (1988) 2557-2563
16. Calderhead D.M., Buhlmann J.E., van den Eertwegh A.J., Claassen E., Noelle R.J., and Fell H.P. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 151 10 (1993) 5261-5271
17. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3 1 (1995) 87-98
18. Granelli-Piperno A., and Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol 147 8 (1991) 2734-2739
19. Thomas R.S., Tymms M.J., McKinlay L.H., Shannon M.F., Seth A., and Kola I. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 14 23 (1997) 2845-2855
20. Bendall H.H., Scherer D.C., Edson C.R., Ballard D.W., and Oltz E.M. Transcription factor NF-kappaB regulates inducible Oct-2 gene expression in precursor B lymphocytes. J Biol Chem 272 46 (1997) 28826-28828
21. Messer G., Weiss E.H., and Baeuerle P.A. Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. Cytokine 2 6 (1990) 389-397
22. Chan H., Bartos D.P., and Owen-Schaub L.B. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 19 3 (1999) 2098-2108
23. Mori N., Fujii M., Cheng G., Ikeda S., Yamasaki Y., Yamada Y., et al. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes 22 3 (2001) 279-287
24. Hettmann T., DiDonato J., Karin M., and Leiden J.M. An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis. J Exp Med 189 1 (1999) 145-158
25. Moriuchi H., Moriuchi M., and Fauci A.S. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 158 7 (1997) 3483-3491
26. Baetu T.M., Kwon H., Sharma S., Grandvaux N., and Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 167 6 (2001) 3164-3173
27. Castellanos M.C., Munoz C., Montoya M.C., Lara-Pezzi E., Lopez-Cabrera M., and de Landazuri M.O. Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1. J Immunol 159 11 (1997) 5463-5473
28. Young H.A. Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 16 8 (1996) 563-568
29. Sweetser M.T., Hoey T., Sun Y.L., Weaver W.M., Price G.A., and Wilson C.B. The roles of nuclear factor of activated T cells and ying-yang 1 in activation-induced expression of the interferon-gamma promoter in T cells. J Biol Chem 273 52 (1998) 34775-34783
30. Campbell P.M., Pimm J., Ramassar V., and Halloran P.F. Identification of a calcium-inducible, cyclosporine sensitive element in the IFN-gamma promoter that is a potential NFAT binding site. Transplantation 61 6 (1996) 933-939
31. Biggs J.R., Kudlow J.E., and Kraft A.S. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 271 2 (1996) 901-906
32. Serfling E., Avots A., and Neumann M. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta 1263 3 (1995) 181-200
33. Ashburner B.P., Westerheide S.D., and Baldwin Jr. A.S. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21 20 (2001) 7065-7077
34. Sheppard K.A., Rose D.W., Haque Z.K., Kurokawa R., McInerney E., Westin S., et al. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19 9 (1999) 6367-6378
35. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5 5 (2004) 392-401
36. Rahman M.M., Kukita A., Kukita T., Shobuike T., Nakamura T., and Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101 9 (2003) 3451-3459
37. Yin L., Laevsky G., and Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276 48 (2001) 44641-44646
38. Takada Y., Gillenwater A., Ichikawa H., and Aggarwal B.B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281 9 (2006) 5612-5622
39. Chen L., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 5535 (2001) 1653-1657
40. Kiernan R., Bres V., Ng R.W., Coudart M.P., El Messaoudi S., Sardet C., et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278 4 (2003) 2758-2766
41. Hu J., and Colburn N.H. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 3 2 (2005) 100-109
42. Chen L.F., Mu Y., and Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21 23 (2002) 6539-6548
43. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., and Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 94 7 (1997) 2927-2932